IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Lorraine E. Pena et al.

DOCKET NO.:

6193/1/US

SERIAL NO.:

10/072,492

GROUP ART UNIT:

1615

FILED:

February 5, 2002

EXAMINER:

Unknown

TITLE:

COMPOSITION FOR RECTAL DELIVERY OF A LINCOSAMIDE

ANTIBACTERIAL DRUG

DATE:

September 4, 2002

CERTIFICATE OF MAILING

I hereby certify that this document and accompanying documents referred to herein are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, U.S. Patent and Trademark Office, Box DD,

Washington, DC 20231 on September 4, 2002.

√ Katriadakis

INFORMATION DISCLOSURE STATEMENT, UNDER 37 CFR §1.97(b)

Assistant Commissioner for Patents U.S. Patent and Trademark Office Box DD Washington, DC 20231

Sir:

Applicants hereby submit copies of patents, publications or other information of which they are aware that they believe may be material to the examination of this application, and in respect of which there may be a duty to disclose under 37 CFR § 1.56. A list of all enclosed documents is provided in a PTO Form 1441, transmitted herewith.

This information disclosure statement is being filed within three months of the filing date of the above-cited patent application or prior to the mailing of a first Office action on the merits, in accordance with 37 CFR § 1.97(b). Accordingly, Applicants

respectfully request that the statement be considered by the Office, in the course of prosecution of the application.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 CFR §1.97(g)), an admission that the information cited is or is considered to be, material to patentability, or that no other material information exists.

Dated: Sept. 4, 2002

Karen B. King

Reg. No.: 41,898